Form 8-K - Current report:
SEC Accession No. 0001698530-25-000044
Filing Date
2025-05-28
Accepted
2025-05-28 17:17:59
Documents
14
Period of Report
2025-05-21
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K xcur-20250521.htm   iXBRL 8-K 27286
2 EX-99 aex991pressreleasemay282025.htm EX-99 8892
6 exicureimage1a10a.gif GRAPHIC 2794
  Complete submission text file 0001698530-25-000044.txt   162293

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xcur-20250521.xsd EX-101.SCH 1788
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xcur-20250521_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xcur-20250521_pre.xml EX-101.PRE 13050
16 EXTRACTED XBRL INSTANCE DOCUMENT xcur-20250521_htm.xml XML 2813
Mailing Address 2430 N. HALSTED ST. CHICAGO IL 60614
Business Address 2430 N. HALSTED ST. CHICAGO IL 60614 847-673-1707
EXICURE, INC. (Filer) CIK: 0001698530 (see all company filings)

EIN.: 815333008 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39011 | Film No.: 25996562
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)